QUALITY CHOICE (CHAIN DRUG MARKETING ASSOCIATION) - Výsledky vyhľadávania

Európska únia - nórčina - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriasis - immunsuppressive - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Európska únia - nórčina - EMA (European Medicines Agency)

fasenra

astrazeneca ab - benralizumab - astma - legemidler for obstruktive sykdommer i luftveiene, - fasenra er angitt som et tillegg på vedlikehold behandling hos voksne pasienter med alvorlig eosinofil astma ikke kontrollert til tross for høye doser inhalasjonssteroider pluss langtidsvirkende beta-agonister.

Európska únia - nórčina - EMA (European Medicines Agency)

lamzede

chiesi farmaceutici s.p.a. - velmanase alfa - alpha-mannosidosis - andre alimentary tract and metabolism products, - behandling av ikke-nevrologiske manifestasjoner hos pasienter med mild til moderat alfa-mannosidosis.